BLUE JET HEALTHCARE Latest Share Price (BLUEJET)
TODAY IN ONE LINE
BLUEJET fell 1.6% on light volume, lagging Nifty's 0.1% move.
With a market cap of ₹10,778.31 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
BLUE JET HEALTHCARE flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 19.3% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 18.2%
- ●Healthy Operating MarginsOPM is structurally strong at 35.8%
- ●High Promoter HoldingPromoters hold 73.2% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 41.5% YoY
- ●Sales ContractionQuarterly sales dropped 69.1% YoY
- ●Promoter SellingPromoter holding decreased by 6.66% QoQ
- ●Rising Receivables vs SalesReceivables grew 97.1% outpacing sales growth of 44.7%
Latest BLUE JET HEALTHCARE News
What changed recently?
Recent events, corporate actions, and announcements.
BLUE JET HEALTHCARE valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for BLUE JET HEALTHCARE, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
BLUE JET HEALTHCARE technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for BLUE JET HEALTHCARE — derived from the latest tape, not yesterday's close.
BLUE JET HEALTHCARE last traded at ₹569.8 with an intraday range of ₹565.5–₹584 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹569.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 617.70 | +47.90 | +8.41% |
| R3 | 599.20 | +29.40 | +5.16% |
| R2 | 591.60 | +21.80 | +3.83% |
| R1 | 580.70 | +10.90 | +1.91% |
| PIVOT | 573.10 | 3.30 | 0.58% |
| CURRENT | 569.80 | — | — |
| S1 | 562.20 | -7.60 | -1.33% |
| S2 | 554.60 | -15.20 | -2.67% |
| S3 | 543.70 | -26.10 | -4.58% |
| S4 | 525.20 | -44.60 | -7.83% |
BLUEJET is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹579.2–₹584
Trading Below opening range, showing Bearishness
BLUE JET HEALTHCARE financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for BLUE JET HEALTHCARE — consolidated or standalone — with margins, YoY growth and key ratios inline.
BLUE JET HEALTHCARE reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹10,778.31 Cr. and reported EPS of ₹4.51.
BLUE JET HEALTHCARE segment analysis : revenue and profit mix.
Disclosed business segments at BLUE JET HEALTHCARE with their share of revenue and profit, switchable between consolidated and standalone reporting.
BLUE JET HEALTHCARE discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for BLUE JET HEALTHCARE.
Our AI distills the core fundamental drivers supporting BLUE JET HEALTHCARE, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
BLUE JET HEALTHCARE's investment case rests on 11 positive markers and 11 flagged concerns drawn from the latest reported filings.
What you're getting.
Exceptional ROCE 57.30% far exceeds pharmaceutical sector median benchmarks significantly
Operating margin 28.51% demonstrates strong pricing power and operational efficiency gains
Net profit margin 27.25% TTM outpaces most peer averages in specialty pharma
ROE 18.22% reflects efficient capital deployment and shareholder value creation
Promoter holding 73.15% ensures strong long-term alignment with shareholder interests
Key Risks.
TTM revenue declined 31.10% YoY, signaling significant top-line contraction and demand weakness
Latest quarterly EPS declined 41.60% YoY despite operational efficiency gains persisting
TTM EPS declined 41.50% YoY, reflecting earnings volatility and profitability pressure
P/E ratio 36.49x suggests stretched valuation relative to current earnings multiples
Dividend yield 0.21% offers minimal income to shareholders seeking regular returns
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 13% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.10%.
BLUE JET HEALTHCARE peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — BLUE JET HEALTHCARE is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
BLUE JET HEALTHCARE chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for BLUE JET HEALTHCARE — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
BLUE JET HEALTHCARE delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for BLUE JET HEALTHCARE over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in BLUE JET HEALTHCARE stood at 62.7% of traded volume, against a 20-day average of 51.4%.
BLUE JET HEALTHCARE announcements: results, concalls, ratings, M&A.
Filings BLUE JET HEALTHCARE sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
BLUE JET HEALTHCARE files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 124 documents below.
Copy of Newspaper Publication
Blue Jet Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
Updates
Blue Jet Healthcare Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the FY 2025-26'.
Shareholders meeting
Blue Jet Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 21, 2026
Copy of Newspaper Publication
Blue Jet Healthcare Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Blue Jet Healthcare Limited has informed the Exchange about Transcript
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
BLUE JET HEALTHCARE dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue BLUE JET HEALTHCARE has declared, sequenced by announce and record date.
BLUE JET HEALTHCARE corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About BLUE JET HEALTHCARE: business, sector, key facts.
What BLUE JET HEALTHCARE does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
BLUE JET HEALTHCARE operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BLUEJET, BSE: 544009.
Blue Jet Healthcare Limited is a global pharmaceutical company specializing in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). These core products are crucial components used in the production of various pharmaceutical and healthcare products worldwide. Their diverse portfolio caters to a wide range of applications within the healthcare industry, solidifying their position as a significant player in the global pharmaceutical supply chain.
A key aspect of Blue Jet's business is its provision of contrast media intermediates. These are vital components in medical imaging procedures, contributing to improved diagnostics and patient care. Beyond contrast media, they also offer a range of niche pharmaceutical intermediates and APIs, demonstrating a commitment to serving specialized needs within the pharmaceutical sector. This strategic focus on specialized products allows them to cater to specific market demands and maintain a competitive edge.
The company further distinguishes itself by offering contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) services. This encompasses a comprehensive range of services, including end-to-end solutions from the initial process development stage through to the commercialization of new chemical entities (NCEs), advanced intermediates, APIs, and building blocks. This integrated approach allows Blue Jet to provide a complete solution for clients, streamlining the drug development process from inception to market launch.
One of Blue Jet's established product lines is saccharin and its related salts. The development, manufacture, and marketing of this product showcases the company's expertise in both the production and commercialization of pharmaceutical chemicals. The continued success in this area highlights their ability to not only produce high-quality products, but also to effectively market and distribute them globally.
Blue Jet Healthcare Limited maintains a substantial international presence, with operations spanning multiple countries, including India, Norway, France, the United States, Italy, Sweden, and Spain. This global reach allows the company to effectively serve a diverse international clientele and participate in various key pharmaceutical markets. Their long history, dating back to their incorporation in 1968, and their headquarters in Thane, India, further establishes their experience and prominence within the industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about BLUE JET HEALTHCARE (BLUEJET).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of BLUE JET HEALTHCARE (BLUEJET)?
The current share price of BLUE JET HEALTHCARE (BLUEJET) is ₹569.80. Today, the stock has declined by ₹9.20 (1.59%), trading in a range of ₹565.50 to ₹584.00. The stock opened at ₹582.05 with a trading volume of 4,42,380 shares.
02Is BLUE JET HEALTHCARE stock a good investment for long-term?
BLUE JET HEALTHCARE can be considered for long-term investment based on several factors. The company has a market capitalization of ₹10,778.31 Cr., P/E ratio of 0, ROE of 18.22%, and ROCE of 19.25%. The dividend yield stands at 0.21%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of BLUE JET HEALTHCARE stock?
The 52-week high price of BLUE JET HEALTHCARE (BLUEJET) is ₹759.50, while the 52-week low is ₹325.00. Currently trading at ₹569.80, the stock is 75.32% above its 52-week low and 24.98% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy BLUE JET HEALTHCARE stock at the current price?
Whether to buy BLUE JET HEALTHCARE stock at ₹569.80 depends on multiple factors. The stock is currently trading with a P/E ratio of 0 and P/B ratio of 0. Today's performance shows a loss of 1.59%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of BLUE JET HEALTHCARE and when is the next dividend?
BLUE JET HEALTHCARE offers a dividend yield of 0.21%, which means for every ₹100 invested at the current price of ₹569.80, you can expect to receive approximately ₹0.21 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of BLUE JET HEALTHCARE?
BLUE JET HEALTHCARE's key financial metrics include: P/E Ratio: 0, P/B Ratio: 0, ROE: 18.22%, ROCE: 19.25%, Dividend Yield: 0.21%, EPS: ₹4.51, Book Value: ₹78.40, and Debt-to-Equity: 0. The company's market cap stands at ₹10,778.31 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is BLUE JET HEALTHCARE stock performing today in the market?
BLUE JET HEALTHCARE stock opened at ₹582.05 and is currently trading at ₹569.80, showing a decline of ₹9.20 (1.59%). The intraday high is ₹584.00 and low is ₹565.50. The trading volume stands at 4,42,380 shares, indicating moderate market participation today.
08What is the P/E ratio of BLUE JET HEALTHCARE and what does it indicate?
BLUE JET HEALTHCARE has a Price-to-Earnings (P/E) ratio of 0, which means investors are willing to pay 0.00 for every ₹1 of earnings. With an EPS of ₹4.51, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about BLUE JET HEALTHCARE (BLUEJET) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.